BIBProShares Ultra NASDAQ Biotechnology
BIB Fund Description
BIB provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ.
BIB Factset Analytics Insight
BIB, having been around since 2010, is a leveraged play on the NASDAQ Biotechnology Index (which is also tracked in unlevered form by iShares' IBB), and is heavily focused on NASDAQ’s biotechnology and pharmaceutical firms with a large-cap bias. The fund gains its 2x leveraged exposure to the index through several financial instruments (i.e. equity securities, derivatives and money-market instruments), and rebalances its exposure daily. Like all geared funds that rebalance daily, BIB is meant for short-term trading since compounding effects over the long-term could create vast differences from expected returns—for good or for ill.
BIB MSCI ESG Analytics Insight
ProShares Ultra NASDAQ Biotechnology has an MSCI ESG Fund Rating of A based on a score of 5.82 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.
The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. ProShares Ultra NASDAQ Biotechnology ranks in the 40th percentile within its peer group and in the 53th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.
BIB Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of BIB. BIB is rated a N/A out of 5.